Home › Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
 

Keywords :   


Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy

2015-12-02 02:15:49| drugdiscoveryonline Home Page

Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community

Tags: with daily activity trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Weekly Recap: Nippon Paint, AkzoNobel, PPG Top This Weeks Stories
02.11Subtropical Storm Patty Graphics
02.11Subtropical Storm Patty Forecast Discussion Number 1
02.11Subtropical Storm Patty Wind Speed Probabilities Number 1
02.11Subtropical Storm Patty Forecast Advisory Number 1
02.11Subtropical Storm Patty Public Advisory Number 1
02.11Summary for Subtropical Storm Patty (AT2/AL172024)
02.11Tropical Storm Lane Graphics
More »